Chronic Kidney Disease

Results From the STEP Trial in China

October 15th 2021, 3:00pm

Video

A brief overview of the STEP trial and results from intensive blood-pressure control in elderly patients with hypertension.

Unmet Needs in the Management of Heart Failure

October 15th 2021, 2:00pm

Video

Insight on the unmet needs in management of heart failure, specifically regarding access to therapeutic agents that can alter the course of disease.

Results From the EMPEROR-Pooled Analysis

October 8th 2021, 1:30pm

Video

Rajiv Agarwal, MD, MS, reflects on pooled data from the EMPEROR-Reduced and EMPEROR-Preserved trials.

Results From EMPEROR-Preserved: CV Outcomes in Patients With HFpEF

October 8th 2021, 1:00pm

Video

An overview of and results from the EMPEROR-Preserved trial, which tested the effects of empagliflozin in patients with HFpEF.

Results From FIGARO-DKD and FIDELITY: Finerenone + SGLT2 Inhibitors

October 1st 2021, 1:30pm

Video

Considerations for the benefit shown in combining finerenone with SGLT2 inhibitors in patients with type 2 diabetes and CKD.

Practical Implications of the FIDELITY Pooled Analysis

October 1st 2021, 1:00pm

Video

Rajiv Agarwal, MD, MS, considers the practical implications of the FIDELITY pooled analysis and how it may impact clinical practice.

Results From the FIDELITY Pooled Analysis

September 24th 2021, 2:30pm

Video

A review of results from the FIDELITY pooled analysis analyzing finerenone’s impact on cardiorenal morbidity and mortality in patients with type 2 diabetes and CKD.

An Overview of the FIDELITY Pooled Analysis Design

September 24th 2021, 2:00pm

Video

An overview of the FIDELITY analysis, which pooled data from the FIGARO-DKD and FIDELIO-DKD trials in patients with type 2 diabetes and CKD.

Remove Race From Equation Used to Assess Kidney Function, Researchers Say

September 23rd 2021, 4:00pm

Article

Long-awaited reports released Thursday call for eliminating race in estimated glomerular filtration rate equations and point to alternatives in an effort to eliminate disparities in chronic kidney disease.

Results From FIGARO-DKD: Finerenone’s Impact on Type 2 Diabetes and CKD

September 17th 2021, 1:30pm

Video

Rajiv Agarwal, MD, MS, shares expert insight on the results of FIGARO-DKD with respect to the trial’s primary and secondary end points.